Twenty-twenty hindsight: an adjuvant breast cancer trial through the retrospectoscope

Affiliations

¹ Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute; and University of Toronto, Ontario, Canada pgoodwin@mtsinai.on.ca.
² Mayo Clinic, Rochester, MN.
³ Ontario Clinical Oncology Group, Juravinski Hospital and Cancer Center, McMaster University, Hamilton, Ontario, Canada.

Editorial

Pamela J Goodwin et al. J Clin Oncol. 2014.

. 2014 Aug 1;32(22):2284-6.

doi: 10.1200/JCO.2014.55.9344. Epub 2014 Jun 16.

¹ Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute; and University of Toronto, Ontario, Canada pgoodwin@mtsinai.on.ca.
² Mayo Clinic, Rochester, MN.
³ Ontario Clinical Oncology Group, Juravinski Hospital and Cancer Center, McMaster University, Hamilton, Ontario, Canada.

No abstract available

Comment on

Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).
Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O'Regan R, Martino S, Shapiro CL, Schneider CJ, Kimmick G, Burstein HJ, Norton L, Muss H, Hudis CA, Winer EP. Shulman LN, et al. J Clin Oncol. 2014 Aug 1;32(22):2311-7. doi: 10.1200/JCO.2013.53.7142. Epub 2014 Jun 16. J Clin Oncol. 2014. PMID: 24934787 Free PMC article. Clinical Trial.